



Title	Rapid progression to pulmonary arterial hypertension crisis associated with mixed connective tissue disease in an 11-year-old girl
Author(s)	Okura, Yuka; Takezaki, Shunichiro; Yamazaki, Yasuhiro; Yamada, Masafumi; Kobayashi, Ichiro; Ariga, Tadashi
Citation	European journal of pediatrics, 172(9), 1263-1265 https://doi.org/10.1007/s00431-013-2034-3
Issue Date	2013-09
Doc URL	http://hdl.handle.net/2115/56838
Rights	The final publication is available at link.springer.com
Type	article (author version)
File Information	MCTD.pdf



[Instructions for use](#)

1

2 **Rapid progression to pulmonary arterial hypertension crisis associated with mixed connective**
3 **tissue disease in an 11-year-old girl.**

4

5 **Authors:** Yuka Okura¹, Shunichiro Takezaki¹, Yasuhiro Yamazaki¹, Masafumi Yamada¹, Ichiro
6 Kobayashi¹ and Tadashi Ariga¹

7

8 ¹Department of Pediatrics, Hokkaido University Graduate School of Medicine, North 15 West 7,
9 Kita-ku, Sapporo, 060-8638, Japan.

10

11 **Correspondence to:** Yuka Okura, Department of Pediatrics, Hokkaido University Graduate School of
12 Medicine, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan.

13 Phone: 81 11 706 5954, Facsimile: 81 11 706 7898

14 E-mail: okura@med.hokudai.ac.jp

15

16 **Abstract**

17 Mixed connective tissue disease (MCTD) is rare in pediatric rheumatic diseases. Pulmonary
18 arterial hypertension (PAH) associated with MCTD usually progress gradually and is difficult to note at
19 the asymptomatic phase. We report a 10-year-old girl with MCTD complicated with rapidly
20 progressive PAH. Although PAH was not detected by echocardiogram or chest CT scan at the initial
21 examination, it became apparent in 1 year and suddenly came to cardiac arrest during invasive

22 procedure. She was successfully treated with extracorporeal assist and both vasodilative and
23 immunosuppressive medication. Combination of echocardiogram and plasma BNP levels could be a
24 useful marker for the follow-up of such cases. *Conclusion* ; PAH could develop early in the course of
25 pediatric MCTD and needs attention to unexpected acute exacerbation, especially under emotional
26 stress.

27

28 **Keywords**

29 Mixed connective tissue disease, pulmonary arterial hypertension, pulmonary arterial hypertension
30 crisis, pulmonary function test, B-type natriuretic peptide

31

32 **Introduction**

33 Mixed connective tissue disease (MCTD) is characterized by Raynaud phenomenon (RP) or
34 swollen hands, overlapping clinical features of systemic lupus erythematosus, systemic sclerosis, and
35 polymyositis/dermatomyositis in conjunction with the presence of anti-ribonucleoprotein (RNP)
36 antibody. MCTD is rare in children and constitutes 0.6% of pediatric rheumatic diseases [3]. The
37 poor prognosis is associated with the presence of interstitial lung diseases or pulmonary arterial
38 hypertension (PAH). PAH is more severe in adult MCTD, however, tends to progresses gradually [1].

39 Here, we report an 11-year-old girl with rapidly progressive PAH associated with MCTD.

40

41 **Case report**

42 A 10-year-old Japanese girl was referred to our hospital because of RP since the age of nine

43 years. She also showed swollen fingers. Laboratory findings were as follows: white blood cell
44 count $4.1 \times 10^9 /L$ with normal differentiation, hemoglobin 118 g/L, platelet count $216 \times 10^9 /L$,
45 erythrocyte sedimentation rate 32 mm/h, C-reactive protein < 0.2 mg/L, C3 1.00 g/L, C4 0.17 g/L,
46 CH50 59.2 IU/ml, immunoglobulin (Ig) G 19.23 g/L, IgA 2.33 g/L, IgM 1.30 g/L, antinuclear antibody
47 titer > 1: 1,280, and anti-RNP antibodies 152.4 INDEX (normal range; <12.9). Anti-smith antibody,
48 anti-double-stranded DNA antibody, and anti-topoisomerase antibody were all negative. Pulmonary
49 function test (PFT) showed slightly decreased % diffusing capacity of carbon monoxide (%DLCO;
50 65.6%) and normal % vital capacity (%VC; 82%). There was no evidence of PAH or interstitial
51 pneumonia (IP) on either echocardiographic study or chest computed tomography (CT) scan. Plasma
52 B-type natriuretic peptide (BNP) level was 20.5 pg/ml (normal range; <18.4). The chest X-ray
53 showed normal cardiothoracic ratio (CTR) 50% (Fig. 1a). Four months later, she showed elevated
54 serum creatinine kinase, and thus, fulfilled the classification criteria of MCTD according to the
55 Ministry of Health, Labor, and Welfare of Japan. At the age of 11 years, she visited our hospital
56 because of fever, vomit, and general fatigue lasting for two days. She was alert but heavily sweated
57 with cold extremities. Biophysical monitoring showed: blood pressure 126/86 mmHg, body
58 temperature 37.1°C, and SpO₂ 98% on room air. The chest X-ray showed cardiomegaly (CTR 68%),
59 but no apparent infiltrative shadows (Fig. 1b). Echocardiography demonstrated right ventricular
60 dilatation, paradoxical movement of the interventricular septum, and tricuspid regurgitation. These
61 findings suggested PAH rather than other causes of pulmonary hypertension such as interstitial lung
62 diseases. During insertions of catheters, electrocardiography showed wide-QRS bradycardia and
63 subsequently asystole. She needed percutaneous cardiopulmonary support for seven days followed by

64 extracorporeal membrane oxygenation for four days. On the 6th hospital day, systolic pulmonary
65 arterial pressure assessed by right heart catheterization was 60 mmHg. Plasma BNP level was 1,146.3
66 pg/ml. PAH responded to the combination therapy with epoprostenol sodium, bosentan hydrate, and
67 sildenafil citrate (Fig.2). Disseminated intravascular coagulation syndrome, pulmonary hemorrhage,
68 and acute renal failure developed but were overcome by intensive care. During the course, she lost
69 the distal phalanx of the left forefinger due to ischemic necrosis and suffered from paraplegia possibly
70 due to infarct of the anterior spinal artery. Although mild ground-glass opacity suggesting IP or lung
71 edema was observed on chest CT scan one month after her admission, it subsided following
72 combination therapy with methylprednisolone pulse therapy (30 mg/kg/dose for consecutive three
73 days) followed by high-dose prednisolone (PSL) (2 mg/kg/day) and three courses of monthly
74 intravenous cyclophosphamide therapy (500 mg/m²). She was finally discharged from the hospital
75 after 10 months of hospitalization on daily PSL 10 mg/day, azathiopurin 50 mg/day, tadalafil 20 mg/day,
76 bosentan 62.5 mg/day, and beraprost 300 µg/day. A follow-up echocardiography approximated a
77 systolic pulmonary arterial pressure of 30-35 mmHg. BNP levels decreased and remained within
78 normal range despite residual mild cardiomegaly (CTR 60%) (Fig. 1c).

79

80 **Discussion**

81 Although PAH is a life-threatening complication of MCTD, it is difficult to be noted at the
82 asymptomatic phase, because early PAH symptoms mimic those of the underlying MCTD [8]. Heart
83 catheterization is a gold standard for the diagnosis of PAH but is difficult to perform in critically ill
84 cases like our patient. PFT is a noninvasive diagnostic test to detect obstructive or restrictive diseases.

85 Particularly, low and decreasing DLCO and %VC/%DLCO ratio \geq 1.4 are a valuable predictor of the
86 PAH associated with connective tissue disease (CTD) [7,9]. Our case showed a low %VC/%DLCO
87 ratio (1.25) and normal echocardiographic and chest CT scan findings at the initial examination. As
88 well, BNP which is primarily produced by cardiomyocytes of the ventricles of the heart, a biochemical
89 marker for impaired overall cardiac function, was initially near normal levels. These suggest that
90 PAH progressed very rapidly within about one year after the initial examination. Thus, although
91 annual screening of PAH by echocardiography, PFT, and BNP have been recommended in CTD [9],
92 more frequent examinations should be considered.

93 Inflammation-mediated organizing vasculopathy are thought to be involved in the progression
94 of CTD-associated PAH. Immunological and/or inflammatory endothelial damage initially leads to a
95 vascular obliteration characterized by intimal proliferation, medial hyperplasia, and finally irreversible
96 fibrosis of the small pulmonary arteriole walls [2,4]. This is supported by the fact that the survival
97 rate of PAH has been improved by an early diagnosis and the prompt use of immunosuppressants in
98 combination with modern PAH-specific vasodilative drugs such as prostanoid, PDE-5 inhibitors, and
99 endothelin receptor antagonist [5,6]. Consistent with this, the response of PAH to the treatment with
100 both immunosuppressants and vasodilative drugs suggests that the PAH in our case was, at least
101 partially, still reversible. In addition to the slowly progressive inflammatory mechanisms, functional
102 vasospasm due to sympathetic overactivity could be a cause of acute exacerbation of PAH. Invasive
103 procedures could have triggered excessive vasospasms on the basis of underlying subclinically
104 progressed PAH in our case.

105

106 **Conclusion**

107 Rapidly progressive PAH complicating MCTD was successfully treated with extracorporeal
108 circulation and both vasodilative and immunosuppressive medication. PAH could develop early in the
109 course of pediatric MCTD and needs attention to unexpected acute exacerbation, especially under
110 emotional stress.

111

112 **Acknowledgment**

113 The authors thank all the staffs of Hokkaido University Hospital who participated in the care of
114 the patient.

115

116 **References**

117

- 118 1. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC (1999) Long-term
119 outcome in mixed connective tissue disease: longitudinal clinical and serologic findings.
120 Arthritis Rheum 42:899-909
- 121 2. Chatterjee S (2011) Pulmonary hypertension in systemic sclerosis. Semin Arthritis Rheum
122 41:19-37
- 123 3. Mier RJ, Shishov M, Higgins GC, Rennebohm RM, Wortmann DW, Jerath R, Alhumoud E
124 (2005) Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am
125 31:483-496
- 126 4. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF (2005) Autoimmunity

- 127 and pulmonary hypertension: a perspective. Eur Respir J 26:1110-1118
- 128 5. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M (2006) Immunosuppressive therapy
- 129 in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130:182-189
- 130 6. Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M (2012) Clinical characteristics
- 131 and survival of Japanese patients with connective tissue disease and pulmonary arterial
- 132 hypertension: a single-centre cohort. Rheumatology 51:1846-1854
- 133 7. Steen V, Medsger TA, Jr. (2003) Predictors of isolated pulmonary hypertension in patients
- 134 with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48:516-522
- 135 8. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C (2005) The prevalence
- 136 of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at
- 137 the secondary health care level of community-based rheumatologists (the UNCOVER study).
- 138 Arthritis Rheum 52:2125-2132
- 139 9. Yoshida S (2011) Pulmonary arterial hypertension in connective tissue diseases. Allergol Int
- 140 60:405-409
- 141

Figure legends

Fig. 1 Serial chest X-ray at the initial examination (a), acute deterioration (b), and discharge (c)

Fig. 2 Treatment and chronological changes in BNP levels. Extra-corporeal assist was performed for

11 days since her admission to our hospital. BNP level was first measured on the 5th hospital day

during extracorporeal assist. Soon after discontinuation of extra-corporeal assist, BNP level was

1146.3 pg/ml. Abbreviations; PCPS, percutaneous cardiopulmonary support; ECMO, extracorporeal

membrane oxygenation

